Phase I/II Study of Lenalidomide (Revlimid) and GM-CSF in Androgen Independent Prostate Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 30 Jan 2013
At a glance
- Drugs Lenalidomide (Primary) ; Sargramostim
- Indications Prostate cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jul 2012 Primary endpoint identified as 'Prostate-specific-antigen-response-rate'as reported by ClinicalTrials.gov.